Epicillin is an antibiotic that is classified as an aminopenicillin drug. It has properties that are similar to ampicillin, especially in terms of its antibacterial spectrum, bacteriological activity level, and its pharmaceutical properties. It has noteworthy in-vitro activities against the bacteria Pseudomonas aeruginosa. In some trials that are published to date, it has been observed to be effective in treating acute infections of the urinary, respiratory and gastrointestinal tracts, as well as infections of the skin and soft tissues of the body. But it needs studies with regards to its compatibility with other antibacterial agents. It is said to be more effective than ampicillin in the treatment of skin infections. But again further clinical trials will be necessary to determine its efficacy.
Its excellent activity orally and subcutaneously was tested in mice infected with a variety of pathogenic bacteria including strains of Streptococcus pyogenes, some non-penicillinase producing bacteria, and other strains of microorganisms that often cause some serious clinical infections. The evidence suggests that it is similar to ampicillin. It shares physical, biological and chemical properties with the other members of the penicillin family, and the latest studies show that it is effective against certain bacterial infections.
